Voyageur Pharmaceuticals Ltd. (TSX-V: VM) has closed its non-brokered private placement, raising total gross proceeds of $5,005,278.32, the company announced June 5. The offering, conducted under the Listed Issuer Financing Exemption (LIFE), consisted of 30,935,000 units at $0.10 per unit and 15,931,486 flow-through units at $0.12 per FT unit.
Each unit includes one common share and one warrant exercisable at $0.20 for 36 months. The FT units comprise one flow-through common share and one warrant with the same terms. The warrants are not exercisable for 70 days and include an acceleration clause: if the common shares close at or above $0.40 for 10 consecutive trading days after six months, the company may accelerate the expiry to 60 days from notice.
In connection with the offering, Voyageur paid cash commissions of $192,040 for units and $145,802.25 for FT units, issuing 1,920,400 unit broker warrants and 1,215,019 FT unit broker warrants, each exercisable at $0.10 and $0.12 respectively for 12 months.
The company plans to use net proceeds for FDA licensing of its barium contrast product suite, regulatory approvals for Frances Creek bulk sample extraction, Frances Creek exploration and feasibility work, U.S. iodine project development, and general corporate purposes. This funding is critical as Voyageur aims to become the first vertically integrated company in the radiology contrast media drug market, controlling raw material sourcing through final production.
Voyageur owns a 100% interest in the Frances Creek barium sulfate (barite) project in Canada, which management believes hosts a rare high-grade mineral suitable for replacing synthetic barium products with higher quality, lower cost imaging agents. Currently, the world's pharmaceutical barium sulfate is almost entirely synthetically produced.
Insiders subscribed for 900,000 units (1.92% of securities issued), increasing their non-diluted ownership to 0.41%. The participation is considered a related party transaction under MI 61-101 but is exempt from formal valuation and minority approval requirements as the fair market value does not exceed 25% of market capitalization. The board unanimously approved the offering.
The securities were issued under the LIFE Exemption and are not subject to a hold period under Canadian securities laws, though they may be subject to TSXV hold periods. The offering is not registered under the U.S. Securities Act and may not be offered or sold to U.S. persons absent registration or exemption.
For business leaders, this capital raise signals Voyageur's progress toward commercializing its contrast media products. The company's strategy to vertically integrate could disrupt the current market dominated by synthetic products, potentially offering cost advantages and improved imaging quality. The funds allocated for FDA licensing are a crucial step toward entering the U.S. market, the largest medical imaging market globally. Investors should monitor Voyageur's ability to achieve regulatory milestones and transition from a development-stage company to a revenue-generating manufacturer.
A copy of the amended offering document is available on the company's website and on SEDAR+ at www.sedarplus.ca under Voyageur's issuer profile.
